352 related articles for article (PubMed ID: 10027195)
1. FDA treads delicate line between safety and speed.
Oncology (Williston Park); 1999 Jan; 13(1):16. PubMed ID: 10027195
[No Abstract] [Full Text] [Related]
2. Patient group seeks overhaul of FDA clinical trial system in court.
Hede K
J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
[No Abstract] [Full Text] [Related]
3. New FDA breakthrough-drug category--implications for patients.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
[No Abstract] [Full Text] [Related]
4. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
Khozin S; Liu K; Jarow JP; Pazdur R
Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
[No Abstract] [Full Text] [Related]
5. Experimental drugs on trial.
Benderly BL
Sci Am; 2007 Oct; 297(4):92-9. PubMed ID: 17926760
[No Abstract] [Full Text] [Related]
6. Recasting cancer trials.
Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
[No Abstract] [Full Text] [Related]
7. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
8. New FDA breakthrough-drug category--implications for patients.
Ricart AD
N Engl J Med; 2014 Jul; 371(1):89. PubMed ID: 24988580
[No Abstract] [Full Text] [Related]
9. New FDA breakthrough-drug category--implications for patients.
Velleca M
N Engl J Med; 2014 Jul; 371(1):88-9. PubMed ID: 24988579
[No Abstract] [Full Text] [Related]
10. New FDA breakthrough-drug category--implications for patients.
Murray BE
N Engl J Med; 2014 Jul; 371(1):88. PubMed ID: 24988578
[No Abstract] [Full Text] [Related]
11. New FDA breakthrough-drug category--implications for patients.
McClellan M; Sigal E
N Engl J Med; 2014 Jul; 371(1):87-8. PubMed ID: 24988577
[No Abstract] [Full Text] [Related]
12. New FDA breakthrough-drug category--implications for patients.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2014 Jul; 371(1):89-90. PubMed ID: 24988576
[No Abstract] [Full Text] [Related]
13. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
14. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
15. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
Roberts SA; Allen JD; Sigal EV
Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
[TBL] [Abstract][Full Text] [Related]
16. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
17. Legislative reform proposals.
Bruderle TP
Am J Health Syst Pharm; 1996 Sep; 53(17):2083-7. PubMed ID: 8870897
[No Abstract] [Full Text] [Related]
18. Balancing safety, effectiveness, and public desire: the FDA and cancer.
Conti R
Issue Brief (Commonw Fund); 2003 Apr; (615):1-6. PubMed ID: 12693391
[No Abstract] [Full Text] [Related]
19. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
20. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
